COMMUNIQUÉS West-GlobeNewswire

Alira Health Earns EcoVadis Silver Rating, Ranking in the Top 15 Percent Globally
12/02/2026
Recognition underscores the company’s mission-driven approach to sustainability, ethics, and responsible growth FRAMINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Alira Health today announced it has been awarded a [...]
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
12/02/2026
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 [...]
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
12/02/2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Picard Medical/ SynCardia Highlights Successful Bridge-to-Transplant Case at UCSF Health Using the SynCardia Total Artificial Heart
12/02/2026
- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country - TUCSON, Ariz., Feb. 12, 2026 (GLOBE [...]
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology Symposium
12/02/2026
WATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil [...]
Cannara organisera une webdiffusion destinée aux investisseurs le 19 février 2026
12/02/2026
MONTRÉAL, 12 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
Cannara to Host Investor Webcast on February 19th, 2026
12/02/2026
MONTREAL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
12/02/2026
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo [...]
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended [...]
Orion Group Financial Statement Release January–December 2025
12/02/2026
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October– [...]
Notice to the Annual General Meeting of Orion Corporation
12/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 12 FEBRUARY 2026 at 12:05 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of [...]
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/02/2026
PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre- [...]
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
12/02/2026
Third party commercial assessment shows larger than expected potential total addressable market for IGALMI ® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary [...]
Velocity Clinical Research Appoints UK Medical Director
12/02/2026
DURHAM, N.C. , Feb. 12, 2026 (GLOBE NEWSWIRE) -- Velocity Clinical Research today announces the appointment of Dr. Ronnie Beboso as UK Medical Director, strengthening the organization’s medical leadership as it [...]
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
12/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 FEBRUARY 2026 at 13.12 EET The Board of Directors of Orion Corporation decided on a new plan period for [...]
Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend
12/02/2026
The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November, for the [...]

Pages